April 2, 2023

NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.

Robert L. Ferris, MD, PhD, reflects on the status of telehealth in oncology and patient care following the COVID-19 pandemic.

Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.